Suppr超能文献

Omniflow II生物合成血管移植物用于下肢动脉血运重建的长期疗效

Long-term outcomes of Omniflow II biosynthetic vascular graft in lower extremity arterial revascularization.

作者信息

Toktaş Faruk, Çayır Mustafa Çağdaş, Özsin Kadir Kaan, Yavuz Şenol, Göncü Mehmet Tuğrul

机构信息

Department of Cardiovascular Surgery, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey.

Department of Cardiovascular Surgery, Medicine Faculty of Pamukkale University, Denizli, Turkey.

出版信息

Turk Gogus Kalp Damar Cerrahisi Derg. 2018 Jul 3;26(3):407-413. doi: 10.5606/tgkdc.dergisi.2018.15689. eCollection 2018 Jul.

Abstract

BACKGROUND

This study aims to evaluate the patency rates and long-term outcomes of femoro-popliteal bypass procedures with Omniflow II biosynthetic vascular grafts in patients with occlusive vascular disease.

METHODS

This retrospective, observational, clinical study included a total of 93 patients (61 males, 32 females; mean age 56.9±7.4 years; range, 43 to 83 years) who underwent femoro-popliteal bypass in which Omniflow II biosynthetic vascular grafts were used due to peripheral arterial disease. The patients were divided into two groups: 62 patients undergoing femoro-popliteal above-knee bypass and 31 patients undergoing the femoro-popliteal belowknee bypass. We evaluated preoperative clinical characteristics, postoperative graft patency rates, and other clinical results.

RESULTS

The mean follow-up was 44.9±18.8 months in the femoropopliteal above-knee bypass group and 47.3±22.3 months in the femoro-popliteal below-knee bypass group (p=0.302). The cumulative primary graft patency rates of the femoro-popliteal above-knee bypass and femoro-popliteal below-knee bypass groups at three, four, and five years were 98%, 95% and 78% and 86%, 75% and 45%, respectively (log-rank; p=0.312). The cumulative assisted graft patency rates of the femoro-popliteal above-knee bypass and femoro-popliteal below-knee bypass groups at five years were 87.9% and 65.3%, respectively (log-rank; p=0.530).

CONCLUSION

The Omniflow II biosynthetic vascular graft is suitable for above- and below-knee femoro-popliteal bypass procedures. These grafts may be prefered due to high patency rates, low incidence of aneursym formations, and infections.

摘要

背景

本研究旨在评估在患有闭塞性血管疾病的患者中,使用Omniflow II生物合成血管移植物进行股腘动脉搭桥手术的通畅率和长期疗效。

方法

这项回顾性、观察性临床研究共纳入93例患者(男性61例,女性32例;平均年龄56.9±7.4岁;范围43至83岁),这些患者因外周动脉疾病接受了使用Omniflow II生物合成血管移植物的股腘动脉搭桥手术。患者分为两组:62例行股腘动脉膝上搭桥手术的患者和31例行股腘动脉膝下搭桥手术的患者。我们评估了术前临床特征、术后移植物通畅率及其他临床结果。

结果

股腘动脉膝上搭桥手术组的平均随访时间为44.9±18.8个月,股腘动脉膝下搭桥手术组为47.3±22.3个月(p = 0.302)。股腘动脉膝上搭桥手术组和股腘动脉膝下搭桥手术组在3年、4年和5年时的累积原发性移植物通畅率分别为98%、95%和78%以及86%、75%和45%(对数秩检验;p = 0.312)。股腘动脉膝上搭桥手术组和股腘动脉膝下搭桥手术组在5年时的累积辅助移植物通畅率分别为87.9%和65.3%(对数秩检验;p = 0.530)。

结论

Omniflow II生物合成血管移植物适用于股腘动脉膝上和膝下搭桥手术。由于通畅率高、动脉瘤形成和感染发生率低,这些移植物可能更受青睐。

相似文献

1
Long-term outcomes of Omniflow II biosynthetic vascular graft in lower extremity arterial revascularization.
Turk Gogus Kalp Damar Cerrahisi Derg. 2018 Jul 3;26(3):407-413. doi: 10.5606/tgkdc.dergisi.2018.15689. eCollection 2018 Jul.
2
Outcomes of Omniflow® II prosthesis used for revascularization in the femoral tract both in infected and non-infected setting.
J Cardiovasc Surg (Torino). 2023 Dec;64(6):634-644. doi: 10.23736/S0021-9509.23.12692-9. Epub 2023 Jun 12.
4
[Factors determining late patency of aortobifemoral bypass graft].
Srp Arh Celok Lek. 1997 Jan-Feb;125(1-2):24-35.
5
Graft type for femoro-popliteal bypass surgery.
Cochrane Database Syst Rev. 2000(2):CD001487. doi: 10.1002/14651858.CD001487.
6
Outcomes of biosynthetic vascular graft for infrainguinal femoro-popliteal and femoro-distal revascularization.
J Cardiovasc Surg (Torino). 2021 Aug;62(4):369-376. doi: 10.23736/S0021-9509.21.11769-0. Epub 2021 Apr 8.
7
A meta-analysis to compare Dacron versus polytetrafluroethylene grafts for above-knee femoropopliteal artery bypass.
J Vasc Surg. 2014 Aug;60(2):506-15. doi: 10.1016/j.jvs.2014.05.049. Epub 2014 Jun 25.
8
Contemporary results with the biosynthetic glutaraldehyde denatured ovine collagen graft (Omniflow II) in femoropopliteal position.
J Vasc Surg. 2020 May;71(5):1630-1643. doi: 10.1016/j.jvs.2019.08.234. Epub 2019 Dec 20.
9
Graft type for femoro-popliteal bypass surgery.
Cochrane Database Syst Rev. 2010 May 12(5):CD001487. doi: 10.1002/14651858.CD001487.pub2.

本文引用的文献

1
The current position of precuffed expanded polytetrafluoroethylene bypass grafts in peripheral vascular surgery.
J Vasc Surg. 2014 Jul;60(1):120-8. doi: 10.1016/j.jvs.2014.01.062. Epub 2014 Mar 12.
2
Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV).
J Vasc Surg. 2007 Aug;46(2):280-8. doi: 10.1016/j.jvs.2007.03.054. Epub 2007 Jun 27.
4
Artificial blood vessel: the Holy Grail of peripheral vascular surgery.
J Vasc Surg. 2005 Feb;41(2):349-54. doi: 10.1016/j.jvs.2004.12.026.
6
Outcome of ProCol, a bovine mesenteric vein graft, in infrainguinal reconstruction.
Eur J Vasc Endovasc Surg. 2002 Dec;24(6):533-4. doi: 10.1053/ejvs.2002.1710.
7
Graft type for femoro-popliteal bypass surgery.
Cochrane Database Syst Rev. 2000(2):CD001487. doi: 10.1002/14651858.CD001487.
9
Below-knee popliteal and distal bypass with PTFE and vein cuff.
Eur J Vasc Endovasc Surg. 1998 Apr;15(4):327-30. doi: 10.1016/s1078-5884(98)80036-1.
10
The ideal small arterial substitute: a search for the Holy Grail?
FASEB J. 1998 Jan;12(1):43-5. doi: 10.1096/fasebj.12.1.43.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验